Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study

INTRODUCTION: Adequate persistence to antidiabetic treatment is highly important to achieve proper glycemic control. In this study we evaluate the persistence to treatment with dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter-2 inhibitors, and glucagon-like peptide-1 receptor agonist...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Diabetes Ther
Auteurs principaux: Jermendy, György, Kiss, Zoltán, Rokszin, György, Abonyi-Tóth, Zsolt, Wittmann, István, Kempler, Péter
Format: Artigo
Langue:Inglês
Publié: Springer Healthcare 2018
Sujets:
Brief Report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6167279/
https://ncbi.nlm.nih.gov/pubmed/30120754
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-018-0483-4
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires